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ZBTB20 is a sequence-specific 
transcriptional repressor of alpha-
fetoprotein gene
Hai Zhang1,*, Dongmei Cao1,*, Luting Zhou1,*, Ye Zhang1, Xiaoqin Guo1, Hui Li1, Yuxia Chen1, 
Brett T. Spear2, Jia-Wei Wu3, Zhifang Xie1 & Weiping J. Zhang1
Alpha-fetoprotein (AFP) represents a classical model system to study developmental gene regulation 
in mammalian cells. We previously reported that liver ZBTB20 is developmentally regulated and 
plays a central role in AFP postnatal repression. Here we show that ZBTB20 is a sequence-specific 
transcriptional repressor of AFP. By ELISA-based DNA-protein binding assay and conventional gel 
shift assay, we successfully identified a ZBTB20-binding site at −104/−86 of mouse AFP gene, 
flanked by two HNF1 sites and two C/EBP sites in the proximal promoter. Importantly, mutation of 
the core sequence in this site fully abolished its binding to ZBTB20 in vitro, as well as the repression 
of AFP promoter activity by ZBTB20. The unique ZBTB20 site was highly conserved in rat and human 
AFP genes, but absent in albumin genes. These help to explain the autonomous regulation of 
albumin and AFP genes in the liver after birth. Furthermore, we demonstrated that transcriptional 
repression of AFP gene by ZBTB20 was liver-specific. ZBTB20 was dispensable for AFP silencing in 
other tissues outside liver. Our data define a cognate ZBTB20 site in AFP promoter which mediates 
the postnatal repression of AFP gene in the liver.
In mammals, alpha-fetoprotein (AFP) and albumin (ALB) genes are closely related in structure, and 
remain adjacent in genome, with albumin 5′ to AFP gene1. They are simultaneously activated during 
liver specification, but autonomously regulated after birth, with albumin gene active throughout life, 
and AFP gene dramatically repressed to basal line. The mechanism underlying their autonomous reg-
ulation in postpartum liver is still an enigma. On the other hand, due to its high tissue specificity and 
tight temporal regulation of expression, AFP is an ideal model to investigate developmental gene reg-
ulation in mammalian cells1,2. AFP is produced at high levels by the fetal liver and visceral endoderm 
of the yolk sac and at low levels by fetal gut and kidney1. Shortly after birth, AFP gene is dramatically 
repressed, which in liver represents a nearly 10,000-fold reduction of transcription3. In adult liver, AFP 
is normally expressed at extremely low levels, but can be reactivated during hepatocyte proliferation, e.g. 
liver regeneration and hepatocellular carcinogenesis1. The mechanisms about its postnatal repression and 
reactivation are not well defined.
AFP transcription is primarily governed by five distinct regulatory regions: a 250-bp tissue-specific 
promoter, a 600-bp repressor region directly upstream of the promoter4, and three enhancers located 2.5, 
5.0, and 6.5 kb, respectively, upstream of the AFP promoter and named enhancer I (EI), EII, and EIII5,6. 
Postnatal repression of AFP transcription may involve combinatorial action of distinct mechanisms. The 
promoter region harbors multiple binding sites for liver-enriched and ubiquitous transcription factors. 
A region at − 120 from transcription start site (+ 1) can be recognized by hepatocyte nuclear factor 1 
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(HNF-1), nuclear factor 1 (NF-1), and CAAT/enhancer binding protein (C/EBP), and is crucial for the 
promoter activity7–9. A point mutation (G to A) at − 119 of AFP promoter is associated with naturally 
occurring Hereditary Persistence of AFP (HPAFP), which is predicted to improve HNF-1 binding and 
decrease NF-1 binding to the mutant sequence10. Upstream the HNF1 sites, there are glucocorticoid 
responsive element and NKx2.8 site potentially involved in AFP regulation in vitro11–13. The repressor 
region (− 838 to − 250) is essential for AFP postnatal repression in pericentral hepatocytes, but not 
essential for complete AFP repression in the intermediate zone and periportal hepatocytes4,14. The region 
between − 1010 and − 838 is required for Afr2-regulated AFP expression during liver regeneration15. The 
three AFP enhancers are essential for AFP transcription in vivo, and continue to be active in the adult 
liver in a position-dependent manner1. Transgenic studies show that EΙΙΙ may be involved in the AFP 
repression in all hepatocytes except those encircling the central vein16.
Some transcriptional repressors have been implicated to be involved in AFP postnatal repression. There 
is a DNA-binding site located at − 135 of AFP promoter for transcriptional repressor COUP-TF17,18, but 
its physiological significance in regulation AFP transcription is still unknown. Overexpression of c-Jun 
in hepatoma cells inhibits AFP promoter activity in a DNA binding-independent manner19. p53 mediates 
AFP repression by competing with HNF3 to bind DNA in the repressor region − 838/− 250 of AFP gene 
and altering its chromatin structure20–22. p53-null mice display a delay in AFP postnatal repression in 
liver, with eventual repression at 4 months of age23. Zhx2 gene, which encodes a zinc finger and homeo-
box protein, regulates AFP postnatal repression in liver, and its mutation in BALB/cJ mice leads to 5–20 
fold higher adult serum AFP levels24.
Zinc finger protein ZBTB20 is developmentally regulated in liver, and acts as a key repressor of AFP 
gene transcription in liver, the specific ablation of which in liver leads to thousands-fold increase in 
AFP mRNA levels in adulthood25. More interestingly, ZBTB20 is implicated in the reactivation of AFP 
in hepatocellular carcinoma26. So far, ZBTB20 is the strongest repressor of AFP gene transcription. 
However, its target DNA sequence and regulatory mechanisms remain undefined. In present study, we 
demonstrate that the sequence of − 104/− 86 in mouse AFP gene is a cognate ZBTB20-binding site which 
mediates sequence-specific binding to and repression by ZBTB20.
Results
Identification of ZBTB20-binding site for in AFP promoter. Our previous work establishes that 
ZBTB20 directly binds to mouse AFP promoter in the region from − 108 to − 53 (relative to transcrip-
tion start site + 1)25. To further identify the ZBTB20-binding site in AFP gene, we first established an 
ELISA-based DNA-protein binding assay (EDBA) system, in which synthetic biotinylated DNA probe 
was immobilized onto streptavidin-coated plate, and DNA-protein complex was detected by anti-ZBTB20 
antibodies colorimetrically (Fig.  1a). Compared to conventional gel mobility shift assay (EMSA), this 
approach is non-isotopic, quantitative, high-throughput, and more sensitive. EDBA assay revealed that 
ZBTB20 protein bound to AFP − 108/− 53 rather than AFP − 170/− 104 or AFP − 65/− 1 and the bind-
ing was dose-dependent (Fig. 1b,c). Furthermore, in competitive EDBA using excessive unlabelled oli-
gonucleotides with serial deletion at 5′ and/or 3′ end of AFP − 108/− 53 as binding competitors, AFP 
− 104/− 86 was found to be the minimal efficient competitor for binding to ZBTB20. Further deletion at 
either 5′ or 3′ end of AFP − 104/− 86 resulted in a marked reduction in their ZBTB20-binding capacity, 
and 5′ deletion at − 100 (AFP − 100/− 84) or 3′ deletion at − 92 (AFP − 104/− 92) nearly completely 
abolished their binding to ZBTB20 (Fig. 1d), which was also confirmed by EMSA data (Fig. 1e, and data 
not shown).
To characterize DNA sequence critical for ZBTB20 binding, we produced some AFP − 104/− 86 
mutants with different point mutations, and checked their ZBTB20-binding capacity. Competitive 
EDBA showed that the mutation from TT to GG at − 103/− 102 or a single A to G mutation at − 100 
did not alter their binding capacity to ZBTB20, while two nucleotide mutations at − 100/− 99 (AA to 
GG) or − 96/− 95 (TA to CC) or multiple nucleotide mutations at − 101/− 97 (CAACG to TGTAA) 
resulted in a remarkable decrease of their binding to ZBTB20 (Fig. 2a,b). More strikingly, the mutations 
of ACGTAA at − 99/− 94 to GTTCCC or even mutations ACGTA at − 99/− 95 to GTTCC could almost 
completely abolish its ZBTB20-binding capacity, suggesting that − 99/− 95 of AFP gene was required for 
ZBTB20 binding. EMSA also revealed a robust binding of ZBTB20 protein to AFP − 104/− 86, with the 
DNA-protein complex specifically supershifted by anti-ZBTB20 antibodies and abolished by excessive 
unlabeled self competitor, and sequence ACGTA at − 99/− 95 was critical for ZBTB20 binding (Fig. 2c). 
Put together, these data suggest that the ZBTB20-binding site is most likely located in − 104/− 86 in 
mouse AFP promoter and the sequence ACGTA − 99/− 95 is critically involved in its composition.
Functional relevance of the ZBTB20-binding site in AFP promoter. To determine the role of the 
above ZBTB20-binding site in the regulation of AFP transcription by ZBTB20, we mutated the site in 
mouse AFP promoter reporter AFP-837Luc by site-directed mutagenesis (Fig. 3a). Mutation of CAACG 
− 101/− 97 to TGTAA (mutant #5) slightly enhanced its promoter activity and decreased the inhibi-
tory responsiveness to ZBTB20 overexpression in HepG2 cells. Notably, mutation of either ACGTAA 
− 99/− 94 to GTTCCC (mutant #6) or ACGTA − 99/− 95 to GTTCC (mutant #7) led to an approxi-
mately 5-fold increase in the reporter activity compared to wild-type counterpart, which may reflect the 
loss of inhibitory response to endogenous ZBTB20. Very strikingly, unlike its wild-type control, these two 
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mutant reporters exhibited a complete unresponsiveness to ZBTB20 overexpression (Fig. 3b), which was 
confirmed by Western blotting (data not shown). These data strongly suggest that − 104/− 86 of mouse 
AFP gene is a cognate functional ZBTB20-binding site, and ACGTA motif at − 99 to − 95 is essential for 
AFP repression by ZBTB20. Then we compared the sequence − 104/− 86 of mouse AFP gene with that 
of rat and human AFP gene, and found this ZBTB20 site was quite conserved in these species (Fig. 3c), 
suggesting that ZBTB20 may also be required for liver postnatal AFP repression in rat and human.
AFP −104/−86 could be the unique cis-acting element of ZBTB20 in AFP gene. To determine 
if AFP gene harbors multiple ZBTB20-binding sites other than − 104/− 86, we searched 7.6 kb of 5′ 
flanking AFP gene against the sequence of − 104/86, and three potential sites at − 160/− 142, − 267/− 284 
(anti-sense strand), and − 6474/− 6456 were hit significantly (Fig.  4a). By EDBA, AFP − 6474/− 6456 
or − 160/− 142 showed no obvious binding to ZBTB20, while AFP − 284/− 267 had weak binding to 
ZBTB20 (Fig.  4b). To determine if AFP − 284/− 267 is functionally necessary for ZBTB20 to repress 
AFP transcription, we constructed mutant AFP-837Luc reporter, in which anti-sense sequence ACATA 
at − 272/− 276 corresponding to ACGTA at − 104/− 86 site was mutated to GTTCC (Fig. 4c). Compared 
Figure 1. Identification of ZBTB20-binding sequence in AFP promoter by DNA binding assays. Different 
unlabeled probes competed with labeled probe − 108/− 53 to form the DNA-protein complex. (a) Schematic 
demonstration of EDBA system to detect ZBTB20 binding to DNA. Biotinylated-DNA probe was incubated 
with GST fusion protein of ZBTB20, and immobilized onto streptavidin-coated plate. The DNA-protein 
complex was detected by anti-ZBTB20 antibodies colorimetrically. (b) By EDBA, ZBTB20 bound to mouse 
AFP gene fragments − 108/− 53, but rather − 170/− 104 or − 65/− 1. The OD450 readout was blanked by 
GST control. n = 3 experiments. (c) By EDBA, ZBTB20 bound to mouse AFP gene fragment − 108/− 53 
in a dose-dependent manner. n = 3 experiments. (d) Competitive ZBTB20-binding capacity of different 
fragments of the AFP gene in EDBA. 100-fold excess of the unlabeled DNA fragments were included to bind 
to ZBTB20 protein in competition with biotinylated probe − 108/− 53. (e) Competitive ZBTB20-binding 
capacity of different fragments of the AFP gene in mobility shift assay. 10- or 50-fold excess of unlabeled 
fragments from the AFP gene competed with 32P-labeled probe − 108/− 53 for binding to ZBTB20.
www.nature.com/scientificreports/
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with wild-type counterpart, the − 272/− 276 mutant reporter did not show significant alterations either 
in the reporter activity or the inhibitory responsiveness to ZBTB20 overexpression in HepG2 cells. This 
indicated the region of − 284/− 267 might not be functionally active or essential for AFP repression by 
ZBTB20, at least in vitro.
On the other hand, AFP enhancer III (EIII), a potent negative regulatory element in all hepatocytes 
except those encircling the central veins, participates in postnatal AFP repression by negative regula-
tion16. However, the relevant trans-acting factors remain undefined. To determine whether ZBTB20 is 
involved in EIII-mediated negative regulation, we took advantage of the EIII-β gl-Dd transgenic mice16, 
in which EIII was linked to human β -globin promoter-driven H2-Dd expression cassette. The H2-Dd 
transgene expression is limited to one to two layers of hepatocytes surrounding central veins in normal 
adult liver due to EIII-mediated dominant repression. In consistence with the previous report16, real-time 
RT-PCR analysis revealed that liver H2-Dd mRNA levels in 3-week old EIII-H2Dd mice were 15-fold 
higher than wild-type control mice, with no significant decline within 2 months of age. ZBTB20 ablation 
did not significantly increase H2-Dd transgenic expression levels in the liver at the age of day 2 or day 
21 after birth (Fig.  4d), implying that AFP enhancer III-mediated AFP repression was independent of 
ZBTB20. Taken together, these data suggest that AFP − 104/− 86 may be the unique ZBTB20-binding site 
in mouse AFP gene essentially involved in AFP repression in postpartum liver by ZBTB20.
Liver-specific repression of AFP transcription by ZBTB20. To determine whether ZBTB20 also 
contributes to AFP silencing via its cognate ZBTB20 site in AFP gene in normally non-AFP produc-
ing tissues, e.g. adult brain, gut, and spleen, we characterized AFP expression in the different tissues 
from ZBTB20 global knockout mice27. The adult livers from ZBTB20-null mice were found to express 
5,000-fold higher levels of AFP than the littermate control, the increase magnitude of which was similar 
to that we observed in hepatocyte-specific ZBTB20 knockout liver. However, their silenced AFP expres-
sion in brain, kidney, gut, and other tissues than liver was not significantly affected by the loss of ZBTB20 
(Fig. 5). These data suggest that AFP silencing outside liver is independent of ZBTB20, most likely due 
to the absence of relevant transcriptional activators or the presence of other AFP-silencing repressors.
Figure 2. Sequence-specific binding of ZBTB20 to the AFP gene. (a) DNA sequence of wild-type (WT) 
and mutant fragments − 104/− 86 of the AFP gene. The mutant sequence was shown in lower case. (b) 
The competitive ZBTB20-binding capacity of different mutant AFP gene fragments − 104/− 86 in EDBA. 
Biotinylated AFP gene fragments − 104/− 86 bound to ZBTB20 in the presence of 100-fold excess of wt or 
mutant fragments. Mutant fragments #6 and #7 lost the ability to compete with wt probe − 104/− 86. (c) In 
mobility shift assay, ZBTB20 bound to AFP gene fragments − 104/− 86. The DNA-protein complex formed 
by 32P-labeled AFP − 104/− 86 and ZBTB20 was blocked by excessive unlabeled wt probe and supershifted 
by anti-ZBTB20 antibody. The unlabeled mutant fragment #7 lost the ability to compete with labeled WT 
probe to form DNA-protein complex.
www.nature.com/scientificreports/
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Expression analysis for transcriptional regulators in the liver. To evaluate whether dysregulated 
AFP expression in ZBTB20-null liver was associated with the alterations of other regulators of AFP 
transcription, we performed quantitative RT-PCR analysis. In the livers from 6-month old liver-specific 
ZBTB20 knockout mice (LZB20KO), AFP mRNA levels were approximately 6,000-fold higher than the 
basal levels of control littermates (Fig. 6a), however, transcriptional activators such as HNF1α , HNF1β , 
C/EBPα , C/EBPβ , HNF3α , HNF3β , or HNF3γ did not show significant change at the expression levels 
compared to control (Fig.  6b). In addition, the expression levels of AFP repressors NF1, COUP-TF1, 
Zhx2, and p53 in LZB20KO livers did not significantly differ from control (Fig.  6c). To some extent, 
HNF1β was increased, and Zhx2 was decreased in LZB20KO liver, but neither of them reached signifi-
cance. Because some cell proliferation and differentiation regulators, such as c-Jun, have been reported 
to down-regulate AFP promoter in hepatoma cells19,28, we also examined the expression levels of c-Myc, 
c-Jun and Jun B in LZB20KO livers, and found that neither of them were not significantly changed at 
mRNA levels (Fig. 6d). Similar results were also obtained from ZBTB20 global KO mice. Combined with 
above findings, these data suggest that dysregulated AFP expression in absence of ZBTB20 is most likely 
due to the loss of direct ZBTB20 action at its cognate site in AFP gene.
AFP −151/−53 confers ZBTB20 responsiveness on ALB promoter. To understand the struc-
tural basis of the autonomous regulation of AFP and ALB genes after birth, we performed comparative 
analysis of their promoters. Both of these genes harbor two HNF1 sites in the proximal promoter regions. 
Of note, they showed sequence divergence to each other in the regions between the two HNF1 sites. 
Interestingly, ZBTB20-binding sequence was just flanked by these two HNF1 sites in AFP promoter 
(Fig.  7a), which did not share significant homology to the corresponding region of albumin gene. In 
addition, we failed to identify significantly similar ZBTB20-binding sequence in ALB promoter. This 
may explain the unresponsiveness of ALB gene to ZBTB20 and their autonomous regulation in liver 
after birth. To further test this hypothesis, we constructed chimeric promoters, which contained min-
imal length of 5′ flanking sequence upstream − 53 of AFP gene with two HNF1 sites and − 50 to + 2 
of ALB gene with core promoter sequence (Fig.  7b), and examined their reporter responsiveness to 
ZBTB20. The reporter driven by the hybrid promoter of AFP − 178/− 53 and ALB − 50/+ 2 could be 
inhibited by ZBTB20 in HepG2 cells as efficiently as its AFP promoter counterpart AFP-178Luc (Fig. 7c). 
Shortening the 5′ AFP gene to − 151 in the chimeric reporter did not abolish its inhibitory responsive-
ness to ZBTB20. Further deletion of 5′ flanking sequence of AFP promoter beyond − 151 led to dramatic 
reduction in promoter activity. These data suggest that AFP − 151/− 53 region with the ZBTB20-binding 
site can confer inhibitory responsiveness on ALB core promoter.
Taken together, we postulate that AFP gene harbors a cognate ZBTB20-binding site at − 104/− 86 
(Fig. 8), which mediates sequence-specific binding to and postnatal repression by ZBTB20 in liver.
Figure 3. Sequence-dependent repression of AFP promoter activity by ZBTB20. (a) Schematic 
demonstration of the WT and mutant AFP luciferase reporters starting from − 837. The mutant nucleotides 
were shown in lower case. The HNF1 sites at AFP promoter were represented with open ovals. (b) The 
activity and ZBTB20-responsiveness of different mutant AFP reporters in HepG2 cells. The reporter plasmids 
were cotransfected into HepG2 cells with mock control vector (gray bar) or ZBTB20-expressing plasmids 
(black bar). RLU values were normalized to the activity of internal control RL-SV40. n = 3 experiments. 
*P < 0.05, **P < 0.01 vs mock control. (c) Sequence alignment of mouse AFP gene fragment − 104/− 86 with 
mouse albumin gene, and rat and human AFP genes.
www.nature.com/scientificreports/
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Discussion
ZBTB20 is a key transcriptional repressor for AFP postnatal repression in liver. In the present study, we 
define a cognate ZBTB20-binding site located between − 104 and − 86 of the AFP gene, which mediates 
sequence-specific DNA binding to and transcriptional repression by ZBTB20. First, this AFP gene frag-
ment − 104/− 86 is the minimal to bind to ZBTB20 both in gel mobility shift assay and ELISA-based 
DNA-protein binding assay, further deletion at either end of the fragment significantly compromising 
ZBTB20-binding capacity. Second, ACGTA motif at − 99/− 95 in this site is essential for ZBTB20 bind-
ing and repression. Their mutation to GTTCC leads to complete abolishment of the ZBTB20-binding 
capacity and inhibitory responsiveness to ZBTB20 in hepatoma cells. Third, this site is highly conserved 
in rat and human AFP promoter, which may mediate ZBTB20 binding to AFP promoter in vivo25. Last, 
it may be the unique ZBTB20 site in AFP gene. Deletion of 5′ UTR upstream − 151 of AFP gene does 
not significantly alter their inhibitory responsiveness to ZBTB20 in hepatoma cells25, and the efforts to 
Figure 4. Analysis of other potential ZBTB20 sites in AFP gene. (a) Sequence alignment of AFP gene 
fragment − 104/− 86 with − 160/− 142, − 284/− 267, and − 6474/− 6456, respectively. (b) Competitive 
ZBTB20-binding capacity of different AFP gene fragments in EDBA assay. 100-fold excess of AFP gene 
fragments competed with biotinylated fragment − 104/− 86 to bind to ZBTB20. (c) AFP − 276/− 272 mutant 
reporter was repressed by ZBTB20 as effectively as WT counterpart. Schematic demonstration of mutant 
AFP reporter was shown schematically in upper part, with the mutant nucleotides at − 276/− 272 of AFP 
gene reporter indicated in lower case. The reporter plasmids were cotransfected into HepG2 cells with mock 
control vector (gray bar) or ZBTB20-expressing plasmids (black bar). Results are expressed as fold repression 
of luciferase normalized to the internal control RL-SV40. n = 3 experiments. P > 0.1. (d) ZBTB20 ablation 
didn’t compromise the inhibitory activity of AFP Enhancer III in liver. Transgenic mice EIII-β gl-Dd were 
crossed to ZBTB20 global knockout mice, H2-Dd mRNA levels in liver were measured by real-time RT-PCR 
at the age of day 2 and day 21. ZBTB20+/+Tg− (open bar), ZBTB20−/−Tg− (gray bar), ZBTB20+/+Tg+ (black 
bar) ZBTB20−/−Tg+ (slashed bar). The transgenic expression did not differ significantly in ZBTB20-null 
livers. P > 0.05. n = 4 experiments.
www.nature.com/scientificreports/
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demonstrate the possibility of multiple ZBTB20 sites in AFP gene end in vain. Therefore, this ZBTB20 
site may be essential for AFP postnatal repression in liver.
This ZBTB20 site is a previously undefined cis-acting element in AFP gene. Interestingly, it is 
flanked by two HNF1 sites and two C/EBP sites in the promoter region. The most likely scenario is that 
ZBTB20 interferes with transcriptional stimulation by activators (e.g. HNF1, C/EBP) or recruit core-
pressors to inhibit transcription and/or remodel chromatin structure. Although ZBTB20 seems to be a 
promoter-specific factor for AFP gene, it may also alter the transcriptional activity by chromatin looping 
or interaction with long-range regulatory regions29. There is remote possibility that ZBTB20 represses 
AFP transcription via altering the expression levels of other transcription factors. The ZBTB20-null liver 
does not exhibit the aberrant expression of AFP transcriptional activators or significant reduction of the 
transcriptional repressors. AFP enhancer III continues to be active in adult liver, and may be responsible 
for the zonal repression of AFP transcription16. We demonstrate that ZBTB20 deficiency does not alter 
EIII activity in liver, which may rule out the possibility that ZBTB20 participates in EIII-mediated AFP 
zonal repression. Although multiple factors and mechanisms may be involved in postnatal repression of 
AFP in liver, we postulate that ZBTB20 is the key transcriptional repressor of AFP gene, which directly 
binds to and dramatically repress AFP promoter, and its absence leads to dysregulated AFP expression 
in adult liver.
The existence of ZBTB20 site in AFP gene also provides insights into the autonomous regulation 
of AFP and albumin genes in postnatal liver. These two genes closely related in structure with an evo-
lutionary divergence of 300–500 million years1. Although simultaneously activated during developing 
liver, they exhibit divergence in expression after birth, with albumin gene active throughout life, while 
AFP gene dramatically repressed to basal line. Interestingly, the ZBTB20 site is present in AFP promoter 
rather than ALB gene, which at least partly explains the autonomous regulation of AFP and ALB genes 
in liver after birth. The ZBTB20 site renders AFP gene robustly responsive to ZBTB20 repression in 
liver, with the expression declined to basal levels in adulthood. Moreover, disruption of ZBTB20 leads to 
derepressed expression of AFP in adult liver with a magnitude close to that of fetal liver, the pattern of 
which is quite similar to liver albumin expression25. Due to the absence of ZBTB20 sites, albumin gene 
is consistently and robustly expressed in presence of ZBTB20 in normal liver, and its expression is not 
altered by the loss of ZBTB20. To support this notion, it may be worthwhile to examine if introduction 
of a ZBTB20 site into albumin promoter could lead to its postnatal repression in liver. At least, our 
promoter swap experiments showed that AFP − 151/− 53 could confer ZBTB20 inhibitory response to 
albumin gene.
The identification of the cognate ZBTB20 site in AFP gene will facilitate our understanding of the 
biological functions of ZBTB20. Transcription repressors play central roles in gene regulation and vital 
biological processes30–32. As a transcriptional repressor, ZBTB20 plays a variety of important roles in 
multiple systems, as suggested by the severe phenotypes in the mice lacking ZBTB20 and the Primrose 
syndrome associated with ZBTB20 mutations in human27,33. In brain, ZBTB20 is required for hippocam-
pal development and functions25,34,35. In peripheral nervous system, ZBTB20 regulates the differenti-
ation of nociceptive sensory neurons and pain sensation36. In pancreatic beta cells, ZBTB20 acts as a 
transcriptional repressor of fructose-1,6-bisphosphatase 1 (FBP1) gene and thus a positive regulator of 
insulin secretion37. In skeletal, ZBTB20 regulates terminal differentiation of hypertrophic chondrocytes 
and endochondral ossification by repressing Sox9 expression38. In immune system, ZBTB20 regulates 
Figure 5. Liver-specific AFP repression by ZBTB20 in adulthood. By real-time RT-PCR, AFP expression 
levels were measured in liver, gut, brain, and kidney from WT (open bar) or global ZBTB20 KO mice (black 
bar) at the age of 2 months. * P < 0.01. n = 4 experiments.
www.nature.com/scientificreports/
8Scientific RepoRts | 5:11979 | DOi: 10.1038/srep11979
antibody production by B lymphocytes39, and promotes innate immune response of macrophages by 
repressing Iκ Bα gene transcription40. Nevertheless, the cognate target sequences of ZBTB20 have not 
been identified before. The establishment of the ZBTB20 site in AFP gene will help to identify potential 
ZBTB20 sites in other target genes, e.g. FBP1, Sox9, and Iκ Bα , and eventually define their consensus 
sequences. Meanwhile, search ZBTB20 sites in the whole genome by ChIP-seq will be another good 
option to explore ZBTB20 target genes and target sequences. These will enable us to better understand 
the physiological and pathophysiological roles of ZBTB20.
Materials and Methods
Animal models. Liver-specific ZBTB20 knockout mice were described previously25. Global ZBTB20 
knockout mice were generated by targeting the same exon as its conditional knockout mice (unpublished 
data). AFP enhancer III transgenic mice (EIII-β gl-Dd) were described before16, and crossed onto global 
or liver-specific ZBTB20 knockout mice. Genotyping was done by PCR analysis of tail genomic DNA. 
All animal experiments were done in accordance with institutional guidelines, and all the experimental 
protocols were approved by the animal welfare and ethics committee of the Second Military Medical 
University.
DNA plasmids. ZBTB20 expression vector and mouse AFP luciferase reporters AFP-837Luc and 
AFP-1103Luc were described previously25. The AFP-178Luc reporter (− 178 to + 45) was provided by H. 
Nakabayashi12. The AFP/Alb chimeric reporters were constructed by removal of the AFP gene fragment 
immediately downstream 1st HNF1 site (− 52 to + 45) from AFP reporter by SpeI digestion and replace-
ment with a synthesized albumin core promoter (− 52 to + 2). Point mutations in AFP-837Luc reporter 
were generated by mutagenesis using the QuickChange site-directed mutagenesis kit (Stratagene) and 
confirmed by DNA sequencing.
Figure 6. Expression analysis of transcription factors in ZBTB20-null liver. By real-time RT-PCR, liver 
mRNA levels of AFP and transcription factors were compared between control (gray bar) and liver-specific 
ZBTB20 KO (LZB20KO, black bar) mice at the age of 6 months, with 36B4 as internal control. AFP mRNA 
levels in LZB20KO liver were approximately 6,000-fold higher than control (a). The expression levels of 
transcriptional activators HNF1α , HNF1β , C/EBPα , C/EBPβ , HNF3α , HNF3β , and HNF3γ in LZB20KO 
livers did not differ significantly from control (b). HNF1β was increased, but did not reach significance. 
The expression levels of AFP repressors NF1, COUP-TF1, Zhx2, and p53 in LZB20KO livers did not differ 
significantly from control (c). Zhx2 was decreased, but did not reach significance. The expression levels of 
cell proliferation regulators c-Myc, c-Jun, and Jun B in LZB20KO livers did not differ significantly from 
control (d).
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Reporter assay. HepG2 cells were transfected by Effectene (Qiagen), and reporter assay was done as 
described25. Forty-eight hours after transfection, cells were disrupted and subjected to luminescent assay 
in a luminometer (MiniLumat LB9506, Berthold GmbH). SV40-Renilla luciferase plasmid was included 
as internal control to normalize the luciferase activity. The fold repression of transcription was calcu-
lated relative to transcription of the reporters in the presence the relevant empty expression vector and 
normalized to the internal control. Expression of ZBTB20 protein in the transfection was confirmed by 
immunoblotting with anti-ZBTB20 antibodies.
Real-time RT-PCR analysis. Mice were sacrificed and tissues were quick-frozen in liquid nitrogen 
before storage at − 80 °C. Total RNA was extracted from their Trizol (Invitrogen) homogenates. Real-time 
RT-PCR was performed as described25. Every plate included 36B4 gene as internal control. Sequence 
of specific primers for each of the genes is available on request. Results were analyzed with Student’s 
unpaired t-test.
Figure 7. AFP −151/−53 confers ZBTB20 repression on albumin core promoter. (a) Alignment of 
mouse AFP and albumin promoters. HNF1 sites, ZBTB20-binding site, and TATA box in AFP promoter 
were shown, with the arrow indicating SpeI site in AFP promoter used for cloning. (b) Schematic 
demonstration of the chimeric promoters composing of AFP − 151/− 53 or − 178/− 53 (in black) and Alb 
− 50/+ 2 (in gray). Partial sequence adjacent to fusion site was illustrated. The two HNF1 sites of AFP 
promoter were represented as black ovals. (c) ZBTB20 overexpression repressed AFP/Alb chimeric promoter 
reporter activity in HepG2 cells. *. P < 0.001 vs Alb-790Luc. n = 4 experiments. Error bar represented s.d.
Figure 8. Schematic demonstration of ZBTB20 site and other cis-acting elements in proximal AFP 
promoter. ZBTB20 site (black oval) is located between the two HNF1 sites.
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Gel mobility shift assay. Gel mobility shift assay was performed as described25. Briefly, the 
double-stranded oligomers from AFP gene − 108/− 53 or − 104/− 86 were labeled with 32P-ATP by 
T4 polynucleotide kinase. After fifteen-minute incubation of the probe together with ZBTB20 protein 
at room temperature, the binding reactions were separated on a 5% PAGE gel containing 0.5 × TBE. 
Ten-fold or fifty-fold excessive unlabeled oligomers were used as competitors, and 2 μ g of anti-ZBTB20 
antibodies were included in the binding reaction for the supershift assay.
ELISA-based DNA-protein binding assay. Biotinylated oligomers were synthesized and purified by 
HPLC for the binding assay. The 50-μ l binding reaction contained 20 pmol biotinylated oligomers, 200 ng 
GST fusion protein of ZBTB20, and the same binding buffer components as gel shift assay, and was added 
into streptavidin-coated 96-well plate. After 1 hr incubation at room temperature, the plate was washed 
4 times with washing buffer, and then added with 100 μ l anti-ZBTB20 antibodies before one hour incu-
bation at room temperature. After washed 3 times with washing buffer, the wells were added with 100 μ l 
HRP-conjugated secondary antibodies and incubated for 1 hr at room temperature. After washed 5 times, 
the wells were developed with 100 μ l developing solution for 10 minutes, and subsequently added with 
100 μ l stop solution before absorbance reading on a microplate reader (Molecular Devices Inc.) at 450 nm 
with a reference wavelength of 655 nm. For competitive binding, 100-fold excess of unlabeled oligomers 
was included in the binding reaction.
Statistical analyses. We used Student-t test for two groups comparison, and one-way ANOVA for 
the comparison of three or more groups.
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